Skip to content

Monthly research recap

Depression research: October 2026

What October 2026's 25 new studies found, synthesized from the papers below. All Depression research →

The synthesis

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.

Research indexed in October 2026 points in a broadly positive direction for rapid-acting treatments in treatment-resistant depression: a large phase 2b trial of intranasal mebufotenin and an interim esketamine-ECT trial in adolescents both reported symptom and suicidality benefits, and modeled and observational work favored ketamine/esketamine on cost and quality of life. Psilocybin findings were more equivocal, with a small pilot missing its primary anhedonia endpoint while secondary depression measures favored the 25 mg dose, and a review stressing uncertain durability. The main caveats are small samples in several studies, unblinded or modeled designs, short follow-up, and limited long-term safety data.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial. 2026 RCT 20 Mixed Psilocybin 25 mg missed the primary week-1 anhedonia endpoint, but secondary analyses showed greater anhedonia improvement at week 8 and greater MADRS improvement at weeks 1 and 8.
Psilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trial 2026 secondary analysis of RCT 25 Mixed Psilocybin slowed cued task switching about a week after dosing and had inconsistent effects on feedback-driven flexibility, while depressive symptom improvement was not associated with cognitive change.
Autophagic Dysregulation in Depression 2026 thesis (human and preclinical experiments) Supports Spermidine increased autophagy flux and reduced depressive symptom severity in humans, and psilocybin/psilocin enhanced autophagy flux in neuronal cells with modest astrocyte and reduced microglial effects.
Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial. 2026 phase 2b RCT 193 Supports Single intranasal mebufotenin doses reduced MADRS scores more than a 0.3 mg comparator at day 29 (-11.1 and -12.5 vs -5.5 points), with higher response and remission rates and good tolerability.
Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis. 2026 post hoc Bayesian reanalysis of RCT 59 Mixed No outcome showed an overall sex difference across treatments; within psilocybin, females had lower post-treatment anxiety than males, but the sex-by-treatment interaction was inconclusive.
Evaluating whether a therapeutic dose of ketamine exposure during adolescence influences adult vulnerability in rats to commonly abused drugs. 2026 controlled animal experiment No effect Adolescent ketamine exposure did not increase adult ethanol consumption or cocaine place preference in either sex.
Low-dose ketamine modulates brain entropy in treatment-resistant depression: Results from two neuroimaging clinical trials. 2026 secondary analysis of two RCTs Supports Low-dose ketamine increased brain entropy from baseline to day 3 in frontolimbic, cerebellar and neuromodulatory regions, which the authors suggest may relate to its antidepressant effects.
Implicit Self-Death Associations and Symptoms of Depression and Anxiety: A Single-Case Experimental Design 2026 single-case experimental design 4 Mixed A brief mindfulness intervention significantly reduced anxiety but not depression, with no significant baseline-to-maintenance effects and no change in implicit self-death associations.
Esketamine-Associated Lower Urinary Tract Symptoms Suggestive of Bladder Overactivity in Treatment-Resistant Depression: A Case Report 2026 case report 1 Opposes The patient developed urinary urgency and pelvic discomfort after starting intranasal esketamine, improving with mirabegron and resolving after dosing was spaced out.
Adolescents and carers using mindfulness Therapy To END depression (ATTEND): study protocol for a parallel randomised controlled superiority trial of Mindfulness for Adolescents and Carers (MAC) for depression among young people aged 15 to 18 years old with an embedded economic evaluation 2026 RCT protocol 480 Unclear The protocol describes a trial of a mindfulness intervention plus treatment as usual versus treatment as usual alone, with no outcome results reported.
Ketamine Versus Electroconvulsive Therapy for Nonpsychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis 2026 cost-effectiveness analysis Supports Modeled racemic ketamine yielded slightly more QALYs (0.024) than ECT at lower health care and societal costs over 29 weeks.
What is the efficacy of low-dose ketamine for treating depression and other mental health conditions? 2026 review Supports Reports moderate efficacy of ketamine as a rapid-acting treatment for treatment-resistant and bipolar depression, with limited long-term safety data requiring monitoring.
Subanesthetic-dose esketamine-assisted electroconvulsive therapy for suicidal ideation in adolescents with major depressive disorder: Interim trial results 2026 interim RCT report 113 Supports Adjunctive esketamine during ECT produced faster reduction in suicidal ideation and higher response rates (76.8% vs 57.9%) than saline, with similar remission rates and no significant short-term cognitive decline.
Suicidality during intranasal (es)ketamine treatment: A retrospective cohort study. 2026 retrospective cohort 80 Mixed Mean suicidality decreased modestly during intranasal esketamine treatment, but transient or sustained increases occurred in a minority and higher baseline suicidality predicted later worsening.
Spatiotemporal remodeling in habenula marks the onset of depression-related phenotypes 2026 animal study Supports Chronic stress produced temporally organized lateral habenula remodeling and depression-related phenotypes, and ketamine reversed the neuronal adaptations and exerted antidepressant effects when given at onset.
Quality of Life in Patients with Treatment-Resistant Depression Treated with Intranasal Esketamine as Add-On Therapy to an SSRI—A Prospective, Comparative Study in Real-World Clinical Practice 2026 prospective observational cohort 60 Supports Both groups improved in quality of life and depressive severity, with larger absolute changes in the esketamine add-on group, though the authors caution against causal interpretation.
Psilocybin in Treatment-Resistant Depression: Weighing Rapid Antidepressant Effects Against Uncertain Durability 2026 narrative review Mixed Concludes psilocybin with psychological support shows short-term antidepressant activity, with one phase 3 trial meeting its primary endpoint and another not confirming its response hypothesis, while specific drug effect and durability remain uncertain.
Depression: Ketamine quiets an unruly habenula. 2026 commentary Supports Describes evidence that the ~24-hour window of ketamine's antidepressant effects coincides with reduced habenula activation and aversive learning in healthy subjects.
Esketamine alleviates the pain-depression dyad: insights from exploratory transcriptomic profiling and Wnt4-associated molecular alterations within the anterior cingulate cortex 2026 animal experiment Supports A single esketamine dose alleviated pain hypersensitivity, behavioral despair and anhedonia, associated with Wnt4-related molecular changes in anterior cingulate cortex neurons.
Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study 2026 retrospective chart review 72 Mixed Response distribution favored IV over SC esketamine after six sessions but was not statistically significant, and categorical response did not differ at protocol endpoints; dissociation was more frequent with IV.
Effects of Mindfulness-Based Stress Reduction Combined With Perioperative Refined Nursing on Postoperative Sleep Disturbances, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting 2026 retrospective cohort with propensity matching 146 Supports Adding mindfulness-based stress reduction to perioperative nursing was associated with lower anxiety and depression scores, better sleep, and favorable cortisol, IL-6, TNF-alpha and orexin levels.
Longitudinal peripheral DNA methylation remodeling following ketamine-assisted psychotherapy in major depressive disorder 2026 longitudinal observational 10 Supports Depressive symptoms declined markedly after ketamine-assisted psychotherapy, alongside exploratory DNA methylation changes enriched for NOTCH1-related pathways.
Baseline Response Criterion and Changes in Emotional Bias as Markers of Esketamine Response in Treatment-Resistant Depression 2026 observational cohort 106 Supports Patients showed altered facial-emotion processing at baseline, and esketamine responders showed early increases in discrimination sensitivity and less negative categorization of neutral faces by week 4.
Intranasal Esketamine for Treatment-Resistant Depression: A Practical Clinical Guide to Patient Selection, Dosing, Combination Strategies and Adverse-Event Management 2026 review Mixed Argues that esketamine approval trials excluded many real-world patients and leave prescribing questions unresolved, including whether 84 mg outperforms 56 mg and when response should be judged.
The Hidden Therapeutic Bridge: Exploring Psilocybin’s Role in Depression, Inflammation, and Pain – A Narrative Review 2026 narrative review Supports Argues that psilocybin and psilocin show therapeutic potential for depression, anxiety and pain, with mechanisms possibly involving inflammation, the default mode network and mystical experiences.

Points of agreement

  • Multiple rapid-acting agents (ketamine, esketamine, mebufotenin, psilocybin) show antidepressant signal in treatment-resistant depression.
  • Esketamine add-on and adjunctive esketamine during ECT are associated with symptom and suicidality improvement in observational and interim trial data.
  • Ketamine and esketamine appear to act on limbic and habenula circuitry and emotional processing.
  • Reviews consistently flag limited long-term safety and durability data.

Conflicts

  • Psilocybin results are inconsistent: one pilot missed its primary anhedonia endpoint while secondary depression measures favored the drug, and one phase 3 trial met its primary endpoint while another did not confirm its response hypothesis.
  • Suicidality outcomes with esketamine are mixed, with modest mean improvement but transient or sustained worsening in a minority.
  • IV versus SC esketamine response differences were not statistically significant despite directional favoring of IV.

Gaps

  • Durability of antidepressant effects beyond weeks to a few months is largely unestablished.
  • Several key studies are small pilots, single cases, or unblinded observational designs.
  • Long-term safety data, including urinary and cognitive effects, are limited.
  • Adolescent and real-world comorbid populations are underrepresented in trials.
  • Optimal dosing (e.g., 56 vs 84 mg esketamine) and retreatment strategies remain unresolved.
  • Blinding integrity and specific drug versus psychological support effects are uncertain.
Browse these studies in the library